ELI LILLY & CO (LLY) Stock News
NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock - Currency: USD
LLY Latest News, Press Relases and Analysis
Which S&P500 stocks are moving before the opening bell on Friday?
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Market Monitor May 2 ( Microsoft, Meta UP - Eli Lilly DOWN)
Wall Street Rebounds as Microsoft and Meta Impress, Eyes Turn to Jobs Report and Tariff Tensions
Benzinga Bulls And Bears: Lilly, Microsoft, Starbucks — And Markets Fully Recover Tariff Chaos Losses
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
The 9 Best Stocks to Buy Now in May (2025)!
Why Viking Therapeutics Stock Was Victorious This Week
Viking is developing what might be a game-changing medication in the segment. Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days, its price rose by almost 18%, according to data compiled by S&P Global Market Intelligence.
Mentions: VKTX
Why Oatly Stock Zoomed Nearly 16% Higher This Week
The alt-milk purveyor poured its shareholders a beat on its first-quarter bottom line. A bottom-line beat in its latest quarter made Oatly Group (NASDAQ: OTLY) stock quite tasty for investors this week. The dynamic on the bottom line was notably more encouraging, as the company managed to narrow its net loss significantly.
Estée Lauder's Beauty Gains Can't Offset Global Headwinds, Says Analyst
Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on the shares of Estée Lauder Companies Inc (NYSE:EL) and lowered the price forecast from $76.00 to $66.00. Estée Lauder delivered a strong third-quarter earnings beat, driven by improved margins and cost control, with sales at the upper end of guidance. The company updated its FY25 outlook in line with prior estimates, though fourth-quarter EPS guidance came in below expectations. While its recovery plan is yielding po
Eli Lilly bounces back from Thursday's sell-off as analysts rush to the drugmaker's defense
"We do not see the CVS announcement as portending an acceleration in price declines across the space," analysts said in a note to clients Thursday.
Organon price target lowered to $10 from $11 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Organon (OGN) to $10 from $11 and keeps an Underperform rating on the shares. The firm said the company cutting its dividend was a “necessary evil” given the company’s limited pipeline, adding that the move makes strategic sense given Organon’s high leverage and need to diversify from Nexplanon risk. BofA noted that, following the quarterly update, its concern with the stock may not be enough of a reason tot build a new position in t
Lilly to participate in Bank of America Securities 2025 Healthcare Conference
/PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025. Lucas Montarce,...
Down 24% in 2025, Should You Buy This Cheap Stock and Hold for the Long Term?
Since the new CEO took over, the digital payments powerhouse has made progress driving profitable growth. Despite having a strong brand and benefiting from a network effect, competition in the industry is fierce. While the barrage of information can be overwhelming, the fresh financial updates that executive teams provide can give investors a much-needed glimpse into how certain businesses are performing.
Company News for May 2, 2025
Companies In The News Are: CVS, LLY, CAH, ICE.
2 Stocks Down 89% and 15% to Buy Right Now
Unity Software has had a tough few years, but a turnaround appears to be underway -- and the stock could have big upside. Kenvue is a consumer health giant poised to start delivering on its promise. A third of the year is now over, and the stock market has seen incredible levels of volatility across the stretch.
This Cybersecurity Stock Is Beating the Market in 2025. Should You Buy It Hand Over Fist?
Check Point Software Technologies has jumped by 17% so far this year, and it could head higher following its solid quarterly report. The stock trades at an attractive valuation, and accelerating bottom-line growth could send it higher over the long run. Check Point Software Technologies (NASDAQ: CHKP) may not be as popular as some of its peers in the cybersecurity industry, but its stock has delivered a resilient performance so far this year.
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss drug.
Stock market today: Nasdaq surges as AI trade reignites amid Big Tech earnings, Dow, S&P 500 rise for 8th day
Microsoft and Meta's strong earnings reports eased investor fears of an economic slowdown amid President Trump's tariffs.
S&P 500 Gains and Losses Today: Index Rises After Strong Start to Big Tech Earnings
The S&P 500 advanced 0.6% on Thursday, May 1, securing its eighth straight winning session as strong results from Microsoft and Meta helped boost tech stocks.
Amgen posts profit, says tax policy more effective than tariffs
(Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a more effective way to influence U.S. manufacturing. President Donald Trump's administration has opened a national security investigation into pharmaceuticals in a bid to demonstrate why the U.S. needs tariffs to increase domestic manufacturing. "We agree with our peers that the most effective answer is not tariffs, but tax policy," Amgen CFO Peter Griffith said on a conference call.
Mentions: AMGN
Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years?
We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other growth stocks to buy for the next 3 years. On April 29, Dan Ives of Wedbush Securities […]
Explore the top gainers and losers within the S&P500 index in today's session.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug
We recently published a list of 10 Jim Cramer Stocks to Watch Amid Trump Tariff Wars. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks that Jim Cramer discussed. Jim Cramer in a latest program on CNBC talked about the latest signs of de-escalation […]
Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade'
Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.
Why Eli Lilly (LLY) Stock Is Nosediving
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to lower-than-expected profitability and full-year EPS guidance that missed significantly. On the other hand, Eli Lilly narrowly topped analysts' revenue expectations, fueled by surging demand for Mounjaro and Zepbound, which together drove a 45% year-over-year increase in total sales. Still, this was a softer quarter.
How to remove mortgage insurance on an FHA loan
Here’s how to cut this monthly insurance cost it if you’re eligible.
Obesity Drug Price Wars Heating Up as CVS Picks Novo Over Lilly
The obesity drug price wars are finally starting.
Eli Lilly's earnings beat is clouded by Novo news. What it means for investors
We suspect the CVS Health change, which goes into effect on July 1, could put a temporary overhang on Eli Lilly shares.
Which S&P500 stocks have an unusual volume on Thursday?
Let's have a look at what is happening on the US markets on Thursday. Below you can find the S&P500 stocks with an unusual volume in today's session.
What's going on in today's session: S&P500 movers
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.
Thursday's session: gap up and gap down stock in the S&P500 index
Stay tuned for the market movements in the S&P500 index on Thursday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
These S&P500 stocks are moving in today's pre-market session
Pre-market stock analysis of S&P500 stocks on 2025-05-01: top gainers and losers in today's session.
Market Monitor April 18 ( Netflix UP, DOWN)
Wall Street Mostly Lower Amid Trump-Fed Tensions, Nvidia’s Continued Slide
Stay informed with the top movers within the S&P500 index on Thursday.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
Which S&P500 stocks have an unusual volume on Thursday?
Let's have a look at what is happening on the US markets on Thursday. Below you can find the S&P500 stocks with an unusual volume in today's session.
What's going on in today's session: S&P500 movers
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
There are notable gap-ups and gap-downs in today's session.
The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Top S&P500 movers in Thursday's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.